Women in Jordan May Soon Benefit From Imaging Diagnostic Systems's Non-Invasive CTLM(R) Laser Breast Imaging Modality

FORT LAUDERDALE, FL--(Marketwire - July 16, 2012) - Imaging Diagnostic Systems, Inc. (IDSI) (OTCBB: IMDS), a pioneer in laser breast imaging, announced today that it has increased its presence in the Middle East by signing a distribution agreement with Mareen Group Co., to market and sell its Computed Tomography Laser Mammography (CTLM®) System in Jordan.

General Manager of Mareen Group Co., Ahmad Abdulrahman comments: "The non-invasive and dignified CTLM® is predicted to be a welcome addition to the advanced health care system in Jordan. The women of Jordan will hopefully benefit from CTLM® soon. Our sales and engineering teams are ready to support CTLM® and aid the imaging needs of Jordanian patients through this innovative laser breast imaging modality."

Mareen Group Co., is a Medical & Pharmaceutical distribution company well established and based in Kuwait. They have been in operation since 1998, proudly providing various medical and healthcare institutions within Kuwait and the surrounding areas with advanced medical equipment and pharmaceuticals from across the globe. The philosophy of Mareen Group Co., has always been to build close ties with their customers by supporting their every need with prompt professional service and support.

Linda Grable, CEO of Imaging Diagnostic Systems Inc., states, "IDSI is pleased to assign the CTLM® distributorship in Jordan to Mareen Group Co. We are enthusiastic to work with them to make this non-invasive modality accessible to women in Jordan. I'm optimistic that the women in Jordan will benefit from CTLM®'s innovative and dignified breast imaging to help in the diagnosis and management of breast abnormalities."

About Imaging Diagnostic Systems, Inc. Imaging Diagnostic Systems, Inc. is the developer of the CTLM system; a revolutionary optical breast imaging device. Optical mammography is a diffuse optical imaging technique (DOT) that aims at detecting breast cancer. The CTLM® system utilizes patented continuous wave laser technology and computed algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. The CTLM® system has received certification and licenses to sell internationally through the following approvals: European CE marking, Health Canada, China SFDA, UL, ISO 13485:2003 and FDA export certification. Pending Mexico COFEPRIS and Russian GOST-R.

For more information, visit our website: www.imds.com

As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc. is included in the Company's filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.